ROCKVILLE, Md., Dec. 11, 2015 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) announced today the retirement of its Executive Director Sherry Keramidas whose leadership during a 20-year tenure helped advance the healthcare regulatory profession. She will retire on 31 January 2016.
"Sherry has served RAPS and its members during a critical period of change in the healthcare industry," according to RAPS Chairman of the Board Rainer Voelksen. "Her constancy throughout ensured RAPS' mission to provide leading education and professional development opportunities and credentialing to regulatory professionals. The RAPS Board of Directors extends its deepest appreciation to Sherry for her two decades of stewardship and commitment to RAPS members, partners and Board."
"It's been my pleasure to serve RAPS during a period of unprecedented change in the healthcare industry," said Keramidas. "The regulatory environment will continue to rapidly evolve and I retire from RAPS confident that the advancement of its professionals will continue to be the defining commitment of this organization's leadership."
The Board's top priority during the transition to new leadership is to ensure RAPS' continuity in fulfilling day-to-day operations that deliver on the organization's commitment to programming and other essential functions that serve its members and partners. Sherry will help facilitate the transition by working with the Executive Committee of the Board to provide support on specific key initiatives.
The Board has initiated a search for a new executive director and will be announcing a plan for interim leadership in the coming weeks. It has established a Search Committee of the Board and will engage a professional recruiting firm to conduct the search for the permanent executive director.
With questions or for more information, please contact RAPS President Martha A. Brumfield at [email protected].
About RAPS
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with offices in Shanghai and Singapore, and chapters and affiliates worldwide. RAPS.org
CONTACT: Zachary Brousseau
Senior Manager, Communications
RAPS
+1 301 770 2920, ext. 245; [email protected]


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



